Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 51,700 shares, a decrease of 18.1% from the March 31st total of 63,100 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily volume of 55,200 shares, the short-interest ratio is presently 0.9 days.
A number of brokerages have commented on INDP. Zacks Investment Research upgraded shares of Indaptus Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, April 5th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Indaptus Therapeutics in a research report on Monday, January 31st.
Several large investors have recently added to or reduced their stakes in INDP. Marshall Wace LLP purchased a new stake in shares of Indaptus Therapeutics during the third quarter valued at approximately $100,000. Citadel Advisors LLC purchased a new stake in shares of Indaptus Therapeutics during the third quarter valued at approximately $111,000. Geode Capital Management LLC purchased a new stake in shares of Indaptus Therapeutics during the third quarter valued at approximately $214,000. Millennium Management LLC purchased a new stake in shares of Indaptus Therapeutics during the fourth quarter valued at approximately $217,000. Finally, Investment House LLC boosted its stake in shares of Indaptus Therapeutics by 272.8% during the fourth quarter. Investment House LLC now owns 95,629 shares of the company’s stock valued at $545,000 after purchasing an additional 69,976 shares during the period. 22.26% of the stock is owned by hedge funds and other institutional investors.
About Indaptus Therapeutics (Get Rating)
Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.
- Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
- Peak Growth Is Over For Etsy
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Uber Fails To Impress
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
Want More Great Investing Ideas?
- 3 Stocks to DOUBLE This Year
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 9 "MUST OWN" Growth Stocks
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.